Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to US$5.18 billion–US$5.25 billion, ...

(Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2026. Second Quarter 2026 Fina ...

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.